Close
Blog & Resources Camargo Blog June 29th, 2010

The Skinny On a Potential New Treatment of Obesity

Orexigen® Therapeutics is developing a new fixed dose sustained-release (SR) combination of naltrexone and bupropion for the treatment of obesity. The rationale behind the two active ingredients is stated to be:

  • Bupropion acts on the weight control circuit by stimulating the POMC neuron.
  • Naltrexone prevents inhibition of POMC neurons by blocking the action of β-endorphin

Bupropion is currently approved for the treatment of major depressive disorder (WELLBUTRIN) and as an aid to smoking cessation (ZYBAN). Naltrexone is indicated for the treatment of alcohol dependence (VIVITROL) and for the blockage of the effects of exogenously administered opioids (REVIA and several generics).

Orexigen states that the company followed the FDA guidance on weight loss products. Accordingly, the company conducted four phase 3 56 week, randomized, double-blind, placebo-controlled trials. The co-primary endpoints were the proportion of patients achieving at least 5% weight loss and percent change in body weight compared to placebo. According to company presentations, on an intent-to-treat basis, “[a]pproximately 25-33% lost 10% or more of their body weight and 12-16% lost at least 15%”. A summary of the Phase II and IIb and the four Phase 3 trials is here on pages 6-8 (also exploratory trials on smoking cessation and anti-depression in obese depressed patients). Yesterday, at the American Diabetes Association annual meeting, Orexigen presented results of 505 patient/52 site 56-week clinical trial that showed their proposed combination drug product helped diabetes patients lose weight and control their blood sugar better than a placebo.

The NDA was filed March 2010 and accepted for review by FDA on June 1, 2010. Orexigen recently announced that FDA’s Division of Metabolic and Endocrine Drug Products Advisory Committee Meeting is tentatively set for December 7, 2010 to review the NDA.

The weight-loss drug development community is going to learn a lot more about how FDA views this drug category by the end of the year. In addition to the Orexigen product, Vivus’s Qnexa® (phentermine/topiramate CR Capsules) will be reviewed July 15 and Arena’s Lorcaserin (a novel, single agent) is tentatively set for September 16.



Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.


Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.


Contact
Headquarters
9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
800 Taylor Street
Suite 101, Mill No. 1
Durham NC, 27701
Montreal Office
507 Place d'Armes
Suite 1101
Montreal, QC H2Y 2W8, Canada
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights